BCBSM pulling back on GLP-1 coverage
US$ 26.30
is there a natural glp 1 agonist Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential GLP-1 Receptor Agonists – Peripheral
Description
For outcome: No limitation
doi: 10.1016/j.bbadis.2009.12.009
Yet cash-pay barriers keep real-world penetration below 200,000 patients so far, implying enormous headroom once biosimilar pricing compresses
While tirzepatide may achieve greater average weight loss, there is no single best medication for every patient, said Clare Thompson, a general practitioner and weight management services lead at Cadogan Clinic in the United Kingdom
doi: 10.1053/j.gastro.2012.08.002
